Academic Journals Database
Disseminating quality controlled scientific knowledge

Comparative Bioavailability and Pharmacodynamic Aspects of Cyclobenzaprine and Caffeine in Healthy Subjects and the Effect on Drowsiness Intensity

ADD TO MY LIST
 
Author(s): Ronilson A. Moreno | Carlos Eduardo Sverdloff | Rogério A. Oliveira | Sandro Evandir Oliveira | Diego Carter Borges, et al.

Journal: Journal of Bioequivalence & Bioavailability
ISSN 0975-0851

Volume: 01;
Issue: 03;
Start page: 086;
Date: 2009;
VIEW PDF   PDF DOWNLOAD PDF   Download PDF Original page

Keywords: Cyclobenzaprine | Caffeine | Pharmacokinetics | HPLC | Mass spectrometry | Bioavailability

ABSTRACT
A specific, fast and sensitive LC–MS/MS assay was developed for the determination of cyclobenzaprine in human plasma using imipramine as the internal standard (IS). The limit of quantification was 0.05 ng/mL and the method was linear in the range of 0.05 to 50 ng/mL. Thecyclobenzaprine and IS retention times were 2.74±0.2 min and 2.69±0.2 min, respectively.Method intra-batch precision and accuracy ranged from 2.90 to 9.72%, and 91.63 to 107.33%, respectively. Interbatch precision ranged from 3.37 to 10.27%, while Interbatch accuracy ranged from 96.13 to 106.10%. The analytical method was applied to evaluate the pharmacokinetic and relative bioavailability of two different pharmaceutical formulations containing cyclobenzaprine, one test tablet containing 10 mg of cyclobenzaprine plus 60 mg of caffeine (Miosan®/cafeine) and the reference Miosan® containing only 10 mg of cyclobenzaprine, manufactured by the same pharmaceutical company. In addition to the pharmacokinetic analysis, a pharmacodinamic evaluation of the drowsiness intensity during the confinement periodswas conducted in order to evaluate the caffeine effect. This study evaluated 34 subjects in a randomized, 2-period crossover study with 14 days washout period between doses.Based on the 90% confidence interval of the individual ratios (test formulation/reference formulation) for Cmax and AUCinf, it was concluded that the test formulation isbioequivalent to the reference Miosan® with respect to the rate and extent of absorption of cyclobenzaprine and that caffeine had no effect on the relative pharmacokinetic parameters. However, based on the Stanford point analysis, the combination of Miosan® with caffeine in the same tablet formulation significantly decreased the drowsiness intensity observed during the confinement periods.
Why do you need a reservation system?      Save time & money - Smart Internet Solutions